Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy:r

来源 :癌症生物学与医学(英文版) | 被引量 : 0次 | 上传用户:ywg005
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
The ability to modulate the future liver remnant (FLR) is a key component of mod oncologic hepatobiliary surgery practice and has extended surgical candidacy for patients who may have been previously thought unable to survive liver resection. Multiple techniques have been developed to augment the FLR including portal vein embolization (PVE), associating liver partition and portal vein ligation (ALPPS), and the recently reported transhepatic liver venous deprivation (LVD). PVE is a well-established means to improve the safety of liver resection by redirecting blood flow to the FLR in an effort to selectively hypertrophy and ultimately improve functional reserve of the FLR. This article discusses the current practice of PVE with focus on summarizing the large number of published reports from which outcomes based practices have been developed. Both technical aspects of PVE including volumetry, approaches, and embolization agents; and clinical aspects of PVE including data supporting indications, and its role in conjunction with chemotherapy and transarterial embolization will be highlighted. PVE remains an important aspect of oncologic care; in large part due to the substantial foundation of information available demonstrating its clear clinical benefit for hepatic resection candidates with small anticipated FLRs.
其他文献
目的探讨运动与血钙离子的相关性,为临床诊治提供依据。方法选用两组健康人:年龄40~60岁,内科检查无器质性病变,分别为常规心电图正常组和ST-T异常改变组,应用标准Bruce方案
期刊
期刊
Liver cancer, primarily hepatocellular carcinoma(HCC), is a major cause of cancer-related death worldwide. HCC is a suitable model of inflammation-induced cance
目的探讨质子泵抑制剂在临床应用情况及疗效。方法通过收集本院的使用情况、查找文献资料,分析、总结质子泵抑制剂在临床中的应用。结果质子泵抑制剂在治疗酸相关性疾病及联
期刊
期刊
期刊
期刊
期刊